Oramed Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Oramed Pharmaceuticals has a total shareholder equity of $162.9M and total debt of $51.0M, which brings its debt-to-equity ratio to 31.3%. Its total assets and total liabilities are $220.6M and $57.7M respectively.
Key information
31.3%
Debt to equity ratio
US$51.01m
Debt
| Interest coverage ratio | n/a |
| Cash | US$162.05m |
| Equity | US$162.89m |
| Total liabilities | US$57.66m |
| Total assets | US$220.55m |
Recent financial health updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12
Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line
Jan 14Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters
Jan 08Oramed's obesity drug candidate shows decrease in glucose levels
Dec 23We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Dec 04Financial Position Analysis
Short Term Liabilities: ORMP's short term assets ($162.6M) exceed its short term liabilities ($53.2M).
Long Term Liabilities: ORMP's short term assets ($162.6M) exceed its long term liabilities ($4.4M).
Debt to Equity History and Analysis
Debt Level: ORMP has more cash than its total debt.
Reducing Debt: ORMP's debt to equity ratio has increased from 0% to 31.3% over the past 5 years.
Debt Coverage: ORMP's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ORMP's interest payments on its debt are well covered by EBIT.